Navigation Links
SI-BONE, Inc. annuncia la pubblicazione dei dati sulla sicurezza della sorveglianza post-commercializzazione per i primi 5.319 pazienti trattati con il sistema di impianto iFuse Implant System
Date:6/5/2013

SAN JOSE, California, 5 giugno 2013 /PRNewswire/ -- SI-BONE, Inc. (San Jose, California), una società di dispositivi medicali pioniera nell'uso di dispositivi chirurgici a ridotta invasività (MIS) per la fusione dell'articolazione (SI) sacriliaca, ha annunciato oggi la pubblicazione dei dati sulla sicurezza della sorveglianza post-commercializzazione di iFuse Implant System's® per i primi 5.319 pazienti trattati.  Lo studio dal titolo: Analysis of the postmarket complaints database for the iFuse SI Joint Fusion System: a minimally invasive treatment for degenerative sacroiliitis and sacroiliac joint disruption, è stato pubblicato in Medical Devices: Evidence and Research il 28 maggio 2013.  Lo studio era mirato a fornire un'analisi delle lamentele sulla sorveglianza post-commercializzazione tramite la valutazione del database delle lamentele post-commercializzazione di SI-BONE .  L'analisi, che copre un periodo di 4 anni, dall'aprile 2009 al gennaio 2013 e comprende 5.319 pazienti, ha rivelato un tasso di lamentele complessivo post-commercializzazione del 3,8% che comprende un tasso totale di revisione dell'1,8% e un tasso di revisione tardiva postoperatoria dello 0,6%.  Le revisioni nel periodo postoperatorio tardivo sono state eseguite per trattare la ricorrenza della sintomatologia o per dolore persistente di eziologia non determinata in media a 279 giorni dopo l'operazione.1  Questi tassi sono coerenti con serie di casi pubblicati in precedenza di iFuse Implant System che segnalavano a 1-2 anni tassi di revisione successivi al trattamento dall'8% allo 0%.2,3    "Siamo estremamente orgoglioso della sicurezza e dell'efficacia clinica dimostrata dai chirurghi con la procedura the iFuse.  Il nostro obiettivo centrale come società è la sicurezza dei pazienti e un'efficacia della pr
'/>"/>

SOURCE SI-BONE, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SI-BONE, Inc. Announces Spring Society Meeting Attendance
2. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
3. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
4. Nonin Medical annuncia lo spostamento del Centro Assistenza Clienti dalla Svezia ai Paesi Bassi
5. I benefici della tecnologia Hologic per lutilizzo della Tomosintesi in vengono corroborati dalla pubblicazione di uno studio italiano
6. Astute Medical, Inc. patrocinerà il simposio informativo presso il meeting sulla nefrologia in terapia intensiva
7. Lo screening trial sul cancro al seno conclude che lutilizzo della mammografia 3D in combinazione con un esame del seno 2D rileva un numero di tumori significativamente maggiore rispetto al solo esame del seno 2D
8. La nuova tecnologia Elekta per la radioterapia oncologica ridefinirà il futuro della lotta contro i tumori
9. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
10. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
11. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Research and Markets( ... "Future Horizons and Growth Strategies in the ... Country Forecasts" report to their offering. ... European Blood Banking Market 2015 is a new ... suppliers and potential market entrants identify and evaluate ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... Against Rheumatism (EULAR) 2011 Annual Congress.  The conference will take ... and will feature the abstracts as two oral presentations and ... and the poster session will address the prevalence of gout ...
... BROOMFIELD, Colo., April 28, 2011 Biodesix announces the ... of the Addario Lung Cancer Medical Institute (ALCMI, pronounced ... Cancer) study is recruiting a minimum of 250 subjects ... in the United States. The study collects biospecimens and ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Biodesix Supports Unique Lung Cancer Research Initiative 2Biodesix Supports Unique Lung Cancer Research Initiative 3
(Date:7/2/2015)... ... July 02, 2015 , ... Patton State ... of State Hospitals. Prior to using Winscribe’s dictation and clinical documentation solutions, Patton ... to manage their organization’s dictation and transcription processes. , Over the ...
(Date:7/1/2015)... ... ... In the United States, summer has always been the season to travel ... Dubai, the summer temperatures are so hot, that July vacationers often leave their home ... ORA Dentistry Spa notes that a trip to the United States, and Los Angeles ...
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... ... July 01, 2015 , ... A healthy eating ... chickens and eggs. Eating organic foods and products can help limit the exposure ... friendly than production chicken farming. Choosing home raised chickens and eggs that do ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® will ... of America (HCA), as it further expands its Strategic Alliance Partnership Program for ... this new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon ...
Breaking Medicine News(10 mins):Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 2Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 3Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 4Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... , TUESDAY, Oct. 25 (HealthDay News) -- ... have a major effect on the rate at which ... The study included 144 experienced U.S. male pilots over ... Administration-approved flight simulator test three times over two years. ...
... as angiotensin-receptor blockers could reduce risk of mortality in ... (AS) by 30 per cent over an eight-year period, ... delegates at the Canadian Cardiovascular Congress. The condition is ... shifts how we think about AS by looking at ...
... MONDAY, Oct. 24 (HealthDay News) -- Teens who drink lots ... suggests. But the study authors concede that sodas are ... there,s a chance that the sugar and caffeine from carbonated ... not a cause-and-effect. Soda consumption, for example, may be a ...
... MONDAY, Oct. 24 (HealthDay News) -- Cancer-causing strains of ... for heart disease, even if she doesn,t have any ... suggests. It,s the first investigation of a possible ... of the most common sexually transmitted pathogens in the ...
... A model used to estimate breast cancer survival rates found ... will avoid a breast cancer death because of screening mammography ... published Online First by Archives of Internal Medicine , ... likely to know a cancer survivor than ever before," the ...
... D.C. Pat Furlong founded Parent Project Muscular Dystrophy (PPMD) ... affected by muscular dystrophy with both resources and hope. Now, ... end the disease. She has spearheaded a partnership between PPMD ... open-access publication, PLoS Currents: Muscular Dystrophy, this month. The story ...
Cached Medicine News:Health News:Aging Brain's Decline May Hinge on a Gene 2Health News:Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease 2Health News:Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease 3Health News:Soft Drinks Linked to Violent Tendencies in Teens: Study 2Health News:Soft Drinks Linked to Violent Tendencies in Teens: Study 3Health News:Could HPV Raise Women's Risk for Heart Disease? 2Health News:Could HPV Raise Women's Risk for Heart Disease? 3Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 2Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 3Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 4Health News:Patient advocacy groups turn to open-access publishing to advance research quest 2
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
... capsular bag in cases of damaged or ... for scleral fixation with suture. Robert J. ... recognized from his early experience using the ... need for greater stability when confronted with ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Medicine Products: